{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:01:21Z","timestamp":1791918081140,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1303600"],"award-info":[{"award-number":["2022YFA1303600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304800"],"award-info":[{"award-number":["2022YFC2304800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2303600"],"award-info":[{"award-number":["2022YFC2303600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cgh.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T04:59:00Z","timestamp":1757825940000},"page":"1611-1620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial"],"prefix":"10.1016","volume":"24","author":[{"given":"Rong","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieer","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5320-227X","authenticated-orcid":false,"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.09.009_bib1","article-title":"Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection","year":"2024","journal-title":"World Health Organization"},{"key":"10.1016\/j.cgh.2025.09.009_bib2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.09.009_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.09.009_bib4","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.cgh.2025.09.009_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.09.009_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.09.009_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/infdis\/jix025","article-title":"Off-treatment HBV DNA levels and the prediction of relapse after nucleos(t)ide analogue discontinuation in chronic hepatitis B: a prospective stop study","volume":"215","author":"Cao","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cgh.2025.09.009_bib8","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.09.009_bib9","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients \u2013 FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.09.009_bib10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van B\u00f6mmel","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.09.009_bib11","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/hep.32479","article-title":"Circulating HBV RNA: from biology to clinical applications","volume":"76","author":"Deng","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.09.009_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3350\/cmh.2023.0194","article-title":"Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation","volume":"30","author":"Tsai","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cgh.2025.09.009_bib13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cgh.2019.07.046","article-title":"Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy","volume":"18","author":"Fan","year":"2020","journal-title":"Clinical Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.09.009_bib14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","article-title":"Combining HBV RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B patients","volume":"222","author":"Fan","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cgh.2025.09.009_bib15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.16538","article-title":"Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment","volume":"54","author":"Xia","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.09.009_bib16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jhep.2022.04.022","article-title":"Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"77","author":"Deng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2025.09.009_bib17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.09.009_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jhep.2024.07.019","article-title":"PegIFN alpha\u20132a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: a randomized-controlled trial","volume":"82","author":"Li","year":"2025","journal-title":"J Hepatol"},{"issue":"22","key":"10.1016\/j.cgh.2025.09.009_bib19","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an immunomodulator in chronic hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.09.009_bib20","doi-asserted-by":"crossref","unstructured":"Yuen MF, Lim SG, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med; 387(21):1957\u20131968.","DOI":"10.1056\/NEJMoa2210027"},{"key":"10.1016\/j.cgh.2025.09.009_bib21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.09.009_bib22","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/hep.30474","article-title":"The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis B: a systematic review","volume":"70","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2025.09.009_bib23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.gastro.2023.09.033","article-title":"HBV DNA and HBsAg levels at 24 weeks off-treatment predict clinical relapse and HBsAg loss in HBeAg-negative patients who discontinued antiviral therapy","volume":"166","author":"Sonneveld","year":"2024","journal-title":"Gastroenterology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525007992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525007992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:54:56Z","timestamp":1784663696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525007992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1542356525007992"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.09.009","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}